scispace - formally typeset
A

Andrew G. Nicholson

Researcher at National Institutes of Health

Publications -  512
Citations -  87875

Andrew G. Nicholson is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Lung cancer & Idiopathic pulmonary fibrosis. The author has an hindex of 113, co-authored 477 publications receiving 73860 citations. Previous affiliations of Andrew G. Nicholson include National Yang-Ming University & University College London.

Papers
More filters
Journal ArticleDOI

The IASLC Lung Cancer Staging Project: Analysis of Resection Margin Status and Proposals for Residual Tumor Descriptors for Non-Small Cell Lung Cancer.

John G. Edwards, +144 more
TL;DR: R descriptors have prognostic relevance with R(un) survival stratifying between R0 and R1, and a detailed evaluation of R factor is of particular importance in the design and analyses of clinical trials of adjuvant therapies.
Journal ArticleDOI

Successful Treatment of Endogenous Lipoid Pneumonia due to Niemann–Pick Type B Disease with Whole-Lung Lavage

TL;DR: Bilateral whole-lung lavage was undertaken, leading to symptomatic improvement, lessening of parenchymal opacification on high-resolution computed tomographic scanning, and a marked improvement in resting arterial oxygen tension while breathing air to 10.3 kPa from 8.4 kPa.
Journal ArticleDOI

Benign pulmonary lymphocytic infiltration and amyloidosis: computed tomographic and pathologic features in three cases.

TL;DR: The clinical, radiologic, and pathologic features of three patients with a combination of pulmonary lymphocytic infiltration and amyloid deposition are presented and the distinctive high-resolution computed tomography features that are common to these cases are reported.
Journal ArticleDOI

Transformation to “high grade” neuroendocrine carcinoma as an acquired drug resistance mechanism in EGFR-mutant lung adenocarcinoma

TL;DR: The case of a 46-year-old female with relapsed EGFR exon 19 deletion lung adenocarcinoma treated with erlotinib, and on resistance, cisplatin-pemetrexed is described and it is suggested that such transformation may not be evident at time of progression on TKI therapy.